Zinc status in human immunodeficiency virus type 1 infection and illicit drug use

Marianna K. Baum, Adriana Campa, Shengan Lai, Hong Lai, John Page

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Zinc deficiency is the most prevalent micronutrient abnormality seen in human immunodeficiency virus (HIV) infection. Low levels of plasma zinc predict a 3-fold increase in HIV-related mortality, whereas normalization has been associated with significantly slower disease progression and a decrease in the rate of opportunistic infections. Studies in Miami, Florida, indicated that HIV-positive users of illicit drugs are at risk for developing zinc deficiency, at least partially because of their poor dietary intake. Zinc deficiency characterized by low plasma zinc levels over time enhances HIV-associated disease progression, and low dietary zinc intake is an independent predictor of mortality in HIV-infected drug users. The amount of zinc supplementation in HIV infection appears to be critical, because deficiency, as well as excessive dietary intake of zinc, has been linked with declining CD4 cell counts and reduced survival. More research is needed to determine the optimal zinc supplementation level in HIV-infected patients, to prevent further burden on an already compromised immune system.

Original languageEnglish
JournalClinical Infectious Diseases
Volume37
Issue numberSUPPL. 2
DOIs
StatePublished - Sep 1 2003

Fingerprint

Street Drugs
Virus Diseases
HIV-1
Zinc
HIV
Disease Progression
Mortality
Micronutrients
Opportunistic Infections
CD4 Lymphocyte Count
Drug Users
Immune System
Survival
Research

ASJC Scopus subject areas

  • Immunology

Cite this

Zinc status in human immunodeficiency virus type 1 infection and illicit drug use. / Baum, Marianna K.; Campa, Adriana; Lai, Shengan; Lai, Hong; Page, John.

In: Clinical Infectious Diseases, Vol. 37, No. SUPPL. 2, 01.09.2003.

Research output: Contribution to journalArticle

Baum, Marianna K. ; Campa, Adriana ; Lai, Shengan ; Lai, Hong ; Page, John. / Zinc status in human immunodeficiency virus type 1 infection and illicit drug use. In: Clinical Infectious Diseases. 2003 ; Vol. 37, No. SUPPL. 2.
@article{6cf6477334c34845bc79a71d9d38bedf,
title = "Zinc status in human immunodeficiency virus type 1 infection and illicit drug use",
abstract = "Zinc deficiency is the most prevalent micronutrient abnormality seen in human immunodeficiency virus (HIV) infection. Low levels of plasma zinc predict a 3-fold increase in HIV-related mortality, whereas normalization has been associated with significantly slower disease progression and a decrease in the rate of opportunistic infections. Studies in Miami, Florida, indicated that HIV-positive users of illicit drugs are at risk for developing zinc deficiency, at least partially because of their poor dietary intake. Zinc deficiency characterized by low plasma zinc levels over time enhances HIV-associated disease progression, and low dietary zinc intake is an independent predictor of mortality in HIV-infected drug users. The amount of zinc supplementation in HIV infection appears to be critical, because deficiency, as well as excessive dietary intake of zinc, has been linked with declining CD4 cell counts and reduced survival. More research is needed to determine the optimal zinc supplementation level in HIV-infected patients, to prevent further burden on an already compromised immune system.",
author = "Baum, {Marianna K.} and Adriana Campa and Shengan Lai and Hong Lai and John Page",
year = "2003",
month = "9",
day = "1",
doi = "10.1086/375875",
language = "English",
volume = "37",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Zinc status in human immunodeficiency virus type 1 infection and illicit drug use

AU - Baum, Marianna K.

AU - Campa, Adriana

AU - Lai, Shengan

AU - Lai, Hong

AU - Page, John

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Zinc deficiency is the most prevalent micronutrient abnormality seen in human immunodeficiency virus (HIV) infection. Low levels of plasma zinc predict a 3-fold increase in HIV-related mortality, whereas normalization has been associated with significantly slower disease progression and a decrease in the rate of opportunistic infections. Studies in Miami, Florida, indicated that HIV-positive users of illicit drugs are at risk for developing zinc deficiency, at least partially because of their poor dietary intake. Zinc deficiency characterized by low plasma zinc levels over time enhances HIV-associated disease progression, and low dietary zinc intake is an independent predictor of mortality in HIV-infected drug users. The amount of zinc supplementation in HIV infection appears to be critical, because deficiency, as well as excessive dietary intake of zinc, has been linked with declining CD4 cell counts and reduced survival. More research is needed to determine the optimal zinc supplementation level in HIV-infected patients, to prevent further burden on an already compromised immune system.

AB - Zinc deficiency is the most prevalent micronutrient abnormality seen in human immunodeficiency virus (HIV) infection. Low levels of plasma zinc predict a 3-fold increase in HIV-related mortality, whereas normalization has been associated with significantly slower disease progression and a decrease in the rate of opportunistic infections. Studies in Miami, Florida, indicated that HIV-positive users of illicit drugs are at risk for developing zinc deficiency, at least partially because of their poor dietary intake. Zinc deficiency characterized by low plasma zinc levels over time enhances HIV-associated disease progression, and low dietary zinc intake is an independent predictor of mortality in HIV-infected drug users. The amount of zinc supplementation in HIV infection appears to be critical, because deficiency, as well as excessive dietary intake of zinc, has been linked with declining CD4 cell counts and reduced survival. More research is needed to determine the optimal zinc supplementation level in HIV-infected patients, to prevent further burden on an already compromised immune system.

UR - http://www.scopus.com/inward/record.url?scp=0042761942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042761942&partnerID=8YFLogxK

U2 - 10.1086/375875

DO - 10.1086/375875

M3 - Article

C2 - 12942385

AN - SCOPUS:0042761942

VL - 37

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 2

ER -